Factors associated with diagnostic and treatment intervals for prostate cancer in Queensland, Australia: a large cohort study

Baade, Peter D.; Gardiner, Robert A.; Ferguson, Megan; Youlden, Danny R.; Aitken, Joanne F.; Yaxley, John; Chambers, Suzanne K.

doi:10.1007/s10552-012-9931-z

Cited by 13 publications

(14 citation statements)

References 25 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11 Patient concern about delays between prediagnosis and treatment may relate to concerns that any delay will reduce the chances of a positive treatment outcome. Between September 2012 and August 2013, approximately 42.6% of the patients seen in our center were from out of state (data extracted from our electronic health record system).…”

Section: Discussionmentioning

confidence: 99%

Tools to Expedite the Development of Treatment Plans

Chavez

Singh

Aleman

et al. 2014

Quality Management in Health Care

View full text Add to dashboard Cite

Quality improvement strategies can be used to modify existing health care processes to reduce patient wait times. We undertook a quality improvement project to reduce the time between new patients' initial visits and the finalization of their treatment plans. Initiation of treatment of new patients at the MD Anderson Sarcoma Medical Oncology Clinic can take up to 2 weeks from their initial consultation. Treatment delays result in increased costs and anxiety for the patient, adversely affecting the quality of care provided. We performed detailed process mapping and a cause-and-effect analysis to identify and prioritize opportunities for improvement. Process improvements addressed 2 key causes of delay to develop a finalized treatment plan: (1) insufficient data for decision making at the time of new patient visit and (2) delays in obtaining diagnostic imaging. After implementing our process improvements, the median time to develop a treatment plan decreased by 89% from 70.5 to 7.6 hours. Our process changes involved minimal additional work and had the secondary outcome of resulting in time savings for the clinic team.

show abstract

Section: Discussionmentioning

confidence: 99%

Tools to Expedite the Development of Treatment Plans

Chavez

Singh

Aleman

et al. 2014

Quality Management in Health Care

View full text Add to dashboard Cite

show abstract

“…Around 34% of the ProsCan study cohort were aged 40–59 years at diagnosis and 45% were aged 60–69 years. Around 92% (986/1064) of participants had localized cancer …”

Section: Methodsmentioning

confidence: 99%

“…For our costing analysis, we used data collected through Medicare records and diagnosis and treatment details collected in self‐administered questionnaires . We used a two‐step approach to estimate the MBS and PBS costs attributable to prostate cancer.…”

Section: Methodsmentioning

confidence: 99%

What does it cost Medicare to diagnose and treat men with localized prostate cancer in the first year?

Mervin

Lowe

Gardiner

et al. 2017

Asia-Pac J Clin Oncol

View full text Add to dashboard Cite

The costs of treating and managing prostate cancer are high and these result in a substantial financial burden for the Australian MBS. Costs attributable to prostate cancer appear to vary widely based on initial treatment and these are likely to increase with the introduction of more expensive services and pharmaceuticals. There is a pressing need for better prognostic tools to distinguish between indolent and aggressive prostate tumors to reduce potential over treatment and help ease the burden of prostate cancer.

show abstract

“…Compared to men notified from public hospitals, men notified from private hospitals with localised disease are significantly less likely to receive radical treatment [12] and have positive surgical margins following radical prostatectomy [13]; even after accounting for age and stage of disease at diagnosis. While not population-based, the methods of data collection by the registry were consistent across both private and public hospitals.…”

Section: Introductionmentioning

confidence: 92%

“…There is some evidence that prostate cancer survivors consult their GPs more times annually than age-matched non-cancer patients [15]. Unrestrained, the effect of increasingly early disease diagnosis and treatment will be that the annual cost of prostate cancer management will continue to grow at an alarming pace [12].…”

Section: Introductionmentioning

confidence: 99%

Development of an International Prostate Cancer Outcomes Registry

et al. 2016

View full text Add to dashboard Cite

ObjectivesTo establish a Prostate Cancer Outcomes Registry‐Australia and New Zealand (PCOR‐ANZ) for monitoring outcomes of prostate cancer treatment and care, in a cost‐effective manner.Materials and MethodsStakeholders were recruited based on their interest, importance in achieving the monitoring and reporting of clinical practice and patient outcomes, and in amalgamation of existing registries. Each participating jurisdiction is responsible for local governance, site recruitment, data collection, and data transfer into the PCOR‐ANZ. To establish each local registry, hospitals and clinicians within a jurisdiction were approached to voluntarily contribute to the registry following relevant ethical approval. Patient contact occurs following notification of prostate cancer through a hospital or pathology report, or from a cancer registry. Patient registration is based on an opt‐out model. The PCOR‐ANZ is a secure web‐based registry adhering to ISO 27001 standards. Based on a standardised minimum data set, information on demographics, diagnosis, treatment, outcomes, and patient reported quality of life, are collected.ResultsEight of nine jurisdictions have agreed to contribute to the PCOR‐ANZ. Each jurisdiction has commenced implementation of necessary infrastructure to support rapid rollout. PCOR‐ANZ has defined a minimum data set for collection, to enable analysis of key quality indicators that will aid in assessing clinical practice and patient focused outcomes.ConclusionPCOR‐ANZ will provide a useful resource of risk‐adjusted evidence‐based data to clinicians, hospitals, and decision makers on prostate cancer clinical practice.

show abstract

Factors associated with diagnostic and treatment intervals for prostate cancer in Queensland, Australia: a large cohort study

Abstract: Differences in waiting times for diagnosis and treatment related to access to private hospital care suggest that there are inequities in health-care service provision that are system based.

Cited by 13 publications

References 25 publications

Tools to Expedite the Development of Treatment Plans

Tools to Expedite the Development of Treatment Plans

What does it cost Medicare to diagnose and treat men with localized prostate cancer in the first year?

Development of an International Prostate Cancer Outcomes Registry

Contact Info

Product

Resources

About